ZCI
BBNX

Zevenbergen Capital Investments’s Beta Bionics BBNX Stock Holding History

Zevenbergen Capital Investments’s Portfolio BBNX Stock Details BBNX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-13,350
Closed -$407K – 115
2025
Q4 		$407K Buy
+13,350
New +$356K 0.01% 100

Other funds holding BBNX

EAM
Eventide Asset Management Boston, Massachusetts $6.05B AUM 76.64% 1-Year Est. Return
SCM
Soleus Capital Management Greenwich, Connecticut $2.9B AUM 169.69% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
SCV
Sands Capital Ventures Arlington, Virginia $421M AUM 26.25% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return
VPC
Vestal Point Capital New York $3.58B AUM 189.12% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

Zevenbergen Capital Investments's BBNX Position: Q1 2026 in Review

Zevenbergen Capital Investments sold out of Beta Bionics (BBNX) in Q1 2026, closing a stake of 13,350 shares — an estimated $407K sold.

Zevenbergen Capital Investments first reported a position in BBNX in Q4 2025 and held it in 1 quarter. The position peaked at $407K in Q4 2025. 130 funds tracked by Wall St. Rank hold BBNX as of Q1 2026.

  • Zevenbergen Capital Investments reported no remaining Beta Bionics position as of Q1 2026 after selling out during the quarter.
  • Zevenbergen Capital Investments sold 13,350 Beta Bionics shares in Q1 2026, an estimated $407K.
  • Zevenbergen Capital Investments first reported a position in Beta Bionics in Q4 2025 and held it in 1 quarter.
  • Zevenbergen Capital Investments's Beta Bionics position peaked at $407K in Q4 2025.
  • 130 funds tracked by Wall St. Rank held Beta Bionics as of Q1 2026.

Based on Zevenbergen Capital Investments's 13F filing for Q1 2026, filed 9 Apr 2026.